Search Results for "calcium-channel blockers"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for calcium-channel blockers. Results 11 to 16 of 16 total matches.

Sotatercept (Winrevair) for Pulmonary Arterial Hypertension

   
The Medical Letter on Drugs and Therapeutics • May 13, 2024  (Issue 1702)
/kg SC q3 weeks18 14,000.0019 ER = extended-release; susp = suspension 1. Calcium channel blockers ...
The FDA has approved sotatercept-csrk (Winrevair – Merck), a first-in-class activin signaling inhibitor, to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events in adults with WHO Group 1 pulmonary arterial hypertension (PAH).
Med Lett Drugs Ther. 2024 May 13;66(1702):73-5   doi:10.58347/tml.2024.1702a |  Show IntroductionHide Introduction

Ozanimod (Zeposia) for Ulcerative Colitis

   
The Medical Letter on Drugs and Therapeutics • Sep 20, 2021  (Issue 1633)
de pointes. Concurrent use of ozanimod with both a heart rate-lowering calcium channel blocker ...
The oral sphingosine 1-phosphate (S1P) receptor modulator ozanimod (Zeposia – Bristol Myers Squibb) has been approved by the FDA for treatment of adults with moderately to severely active ulcerative colitis. It is the first S1P receptor modulator to be approved for treatment of ulcerative colitis. Ozanimod was approved in March 2020 for use in adults with relapsing forms of multiple sclerosis.
Med Lett Drugs Ther. 2021 Sep 20;63(1633):147-51 |  Show IntroductionHide Introduction

Comparison Table: Some Oral Antiseizure Medications (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024  (Issue 1708)
(e.g., beta blockers, calcium channel blockers) No adequate studies in pregnant women ...
View the Comparison Table: Some Oral Antiseizure Medications
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e133-40   doi:10.58347/tml.2024.1708b |  Show IntroductionHide Introduction

Drugs for Epilepsy

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024  (Issue 1708)
and in those taking other drugs that may prolong the PR interval, such as beta blockers or calcium channel ...
When used for the appropriate seizure type, antiseizure medications (ASMs) are roughly equivalent in efficacy. In addition to the seizure type, the choice of drug is usually based on factors such as ease of use, spectrum of activity, adverse effects, interactions with other drugs, presence of comorbid conditions, suitability for elderly persons and those with childbearing potential, and cost. Treatment should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures persist, expert clinicians generally...
Med Lett Drugs Ther. 2024 Aug 5;66(1708):121-8   doi:10.58347/tml.2024.1708a |  Show IntroductionHide Introduction

Nonopioid Drugs for Pain

   
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022  (Issue 1645)
), a synthetic neuronal N-type calcium channel blocker, is administered intrathecally via a programmable ...
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. For severe pain, especially severe chronic cancer pain, use of opioids may be necessary. Noninvasive nonpharmacologic treatments, including physical and psychological therapies, have been shown to improve pain and function in patients with some common chronic pain conditions and are unlikely to cause serious harms. A multimodal approach to analgesic therapy can increase pain control while reducing opioid use and adverse effects.
Med Lett Drugs Ther. 2022 Mar 7;64(1645):33-40 |  Show IntroductionHide Introduction

Drugs for Anxiety Disorders

   
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023  (Issue 1682)
release of the excitatory neurotransmitter glutamate from PQ-type voltage-gated calcium channels ...
Anxiety disorders (generalized anxiety disorder, panic disorder, social anxiety disorder, and various phobias) are the most common form of psychiatric illness. They can be treated effectively with cognitive behavioral therapy (CBT) and/or pharmacotherapy.
Med Lett Drugs Ther. 2023 Aug 7;65(1682):121-8   doi:10.58347/tml.2023.1682a |  Show IntroductionHide Introduction